The pivotal trial supporting its 2010 FDA approval enrolled 816 HIV-infected adults with clinically defined lipodystrophy, and Phase 3 data documented visceral fat reductions of roughly 15-18% over 26 weeks of treatment a result robust enough to clear FDA review for a defined medical indication
Metabolic parameters including glucose tolerance, insulin sensitivity, and IGF-1 levels were monitored throughout the treatment period, confirming that the favorable metabolic profile persisted with chronic use
For example, some adults with mild low intake may use an oral supplement, while others with significant deficiency, severe symptoms, or impaired absorption may need physician-directed treatment such as vitamin therapy or injectable replacement
75 Xu, Q
Some athletes or individuals report feeling an overall wellness boost. On the other hand, if your levels were already sufficient, you may not perceive a difference in how you feel (since the body generally doesnt utilize excess beyond its needs)
Its important to check how well the treatment is working and adjust it if needed